Our direct comparison study revealed for the first time that in early breast cancer, PIK3CA hotspot mutations are present in CTCs at a higher percentage before than after treatment, when compared to paired plasma‐ctDNA samples. This evidence concerns the gene PIK3CA and breast carcinoma.